First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis

• Jing-Wen Han ,

  Contributed equally to this work with: Jing-Wen Han, Yu Zhong

  Roles Conceptualization, Formal analysis, Funding acquisition, Supervision, Writing – original draft

  Affiliations Department of Pharmacy, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China, Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China

  https://orcid.org/0009-0002-7391-0809

  ⨯
• Yu Zhong ,

  Contributed equally to this work with: Jing-Wen Han, Yu Zhong

  Roles Methodology, Supervision, Writing – original draft, Writing – review & editing

  Affiliation Department of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou, China

  ⨯
• Jin Zhong,

  Roles Data curation, Investigation, Software, Writing – original draft

  Affiliation Department of Traditional Chinese Medicine, School of Medicine, Xiamen University, Xiamen, China

  ⨯
• Wen-Jing Zeng ,

  Roles Data curation, Supervision, Writing – review & editing

  * E-mail: 29761320@qq.com (L-JS); zengwenjing89@csu.edu.cn (W-JZ)

  Affiliation Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China

  ⨯
• Li-Jun Sun

  Roles Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing

  * E-mail: 29761320@qq.com (L-JS); zengwenjing89@csu.edu.cn (W-JZ)

  Affiliations Department of Oncology, Molecular Oncology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China, Department of Oncology, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital, Fujian Medical University, Fuzhou, China, Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China

  ⨯